James Verbsky, MD, PhD

Associate Professor, Pediatrics (Rheumatology) and Microbiology & Immunology; Medical Director, Clinical Immunology Research Laboratory; Medical Director, Clinical and Translational Research

Locations

Children's Wisconsin
Children's Corporate Center
Suite C465

Contact Information

General Interests

Primary Immune Deficiency, Immune Dysregulation Syndromes

Education

PhD, Immunology, Washington University, 2000
MD, Washington University, 2000
Fellowship, Pediatric Rheumatology, Washington University

Research Interests

My research interests focus on immune regulation, and my research program is based on the premise of taking genetically defined immune deficiencies from humans and modeling these diseases in the laboratory. Since I see patients with immune deficiencies and inflammatory disorders, the first step in this program is to define the immune deficiency in these patients. Using genetic technologies, such as copy number variation analysis, targeted gene sequencing, and next generation genetic sequencing, we have been successful at defining several primary immune deficiencies, and have used these findings to model these diseases in the laboratory to help us understand immunity and immune regulation.

Clinical and histologic presentation of pediatric reactive granulomatous dermatitis.

(Akinshemoyin Vaughn OL, Siegel DH, Chiu YE, DeBord LC, Hogeling M, Hunt RD, Nguyen C, Sokumbi O, Verbsky JW, Arkin LM.) Pediatr Dermatol. 2020 May;37(3):498-503 PMID: 32115758 SCOPUS ID: 2-s2.0-85081024767 03/03/2020
Novel Hemizygous IL2RG p.(Pro58Ser) Mutation Impairs IL-2 Receptor Complex Expression on Lymphocytes Causing X-Linked Combined Immunodeficiency.

(Tuovinen EA, Grönholm J, Öhman T, Pöysti S, Toivonen R, Kreutzman A, Heiskanen K, Trotta L, Toiviainen-Salo S, Routes JM, Verbsky J, Mustjoki S, Saarela J, Kere J, Varjosalo M, Hänninen A, Seppänen MRJ.) J Clin Immunol. 2020 Apr;40(3):503-514 PMID: 32072341 PMCID: PMC7142052 SCOPUS ID: 2-s2.0-85079785911 02/20/2020
Autoinflammatory Disorders with Perinatal Onset.

(Stolberg NG, Verbsky JW.) Clin Perinatol. 2020 Mar;47(1):41-52 PMID: 32000928 SCOPUS ID: 2-s2.0-85078347941 02/01/2020
Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome.

(Yang C, Siebert JR, Burns R, Gerbec ZJ, Bonacci B, Rymaszewski A, Rau M, Riese MJ, Rao S, Carlson KS, Routes JM, Verbsky JW, Thakar MS, Malarkannan S.) Nat Commun. 2019 09 02;10(1):3931 PMID: 31477722 PMCID: PMC6718415 SCOPUS ID: 2-s2.0-85071610251 09/04/2019
Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy.

(Hinze CH, Foell D, Johnson AL, Spalding SJ, Gottlieb BS, Morris PW, Kimura Y, Onel K, Li SC, Grom AA, Taylor J, Brunner HI, Huggins JL, Nocton JJ, Haines KA, Edelheit BS, Shishov M, Jung LK, Williams CB, Tesher MS, Costanzo DM, Zemel LS, Dare JA, Passo MH, Ede KC, Olson JC, Cassidy EA, Griffin TA, Wagner-Weiner L, Weiss JE, Vogler LB, Rouster-Stevens KA, Beukelman T, Cron RQ, Kietz D, Schikler K, Mehta J, Ting TV, Verbsky JW, Eberhard AB, Huang B, Giannini EH, Lovell DJ.) Arthritis Rheumatol. 2019 03;71(3):451-459 PMID: 30225949 PMCID: PMC6393224 SCOPUS ID: 2-s2.0-85060584463 09/19/2018
CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.

(Garcia-Perez JE, Baxter RM, Kong DS, Tobin R, McCarter M, Routes JM, Verbsky J, Jordan MB, Dutmer CM, Hsieh EWY.) Front Immunol. 2019;10:998 PMID: 31156616 PMCID: PMC6532297 SCOPUS ID: 2-s2.0-85067103184 06/04/2019
Damaging BTK Variant Demonstrated by Carrier, Allele-Specific BTK Expression in B Cells and Monocytes.

(Bausch-Jurken MT, Hintermeyer M, Woodliff J, Chen S, Rymaszewski A, Verbsky J, Routes J.) J Clin Immunol. 2019 01;39(1):23-25 PMID: 30627929 SCOPUS ID: 2-s2.0-85059675420 01/11/2019
Identification of molecular signatures of cystic fibrosis disease status with plasma-based functional genomics.

(Levy H, Jia S, Pan A, Zhang X, Kaldunski M, Nugent ML, Reske M, Feliciano RA, Quintero D, Renda MM, Woods KJ, Murkowski K, Johnson K, Verbsky J, Dasu T, Ideozu JE, McColley S, Quasney MW, Dahmer MK, Avner E, Farrell PM, Cannon CL, Jacob H, Simpson PM, Hessner MJ.) Physiol Genomics. 2019 01 01;51(1):27-41 PMID: 30540547 PMCID: PMC6383551 SCOPUS ID: 2-s2.0-85060056850 12/13/2018
Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined immunodeficiency.

(Boutboul D, Kuehn HS, Van de Wyngaert Z, Niemela JE, Callebaut I, Stoddard J, Lenoir C, Barlogis V, Farnarier C, Vely F, Yoshida N, Kojima S, Kanegane H, Hoshino A, Hauck F, Lhermitte L, Asnafi V, Roehrs P, Chen S, Verbsky JW, Calvo KR, Husami A, Zhang K, Roberts J, Amrol D, Sleaseman J, Hsu AP, Holland SM, Marsh R, Fischer A, Fleisher TA, Picard C, Latour S, Rosenzweig SD.) J Clin Invest. 2018 07 02;128(7):3071-3087 PMID: 29889099 PMCID: PMC6026000 SCOPUS ID: 2-s2.0-85049870244 06/12/2018
Newborn Screening for Severe Combined Immunodeficiency.

(Routes J, Verbsky J.) Curr Allergy Asthma Rep. 2018 05 10;18(6):34 PMID: 29749587 SCOPUS ID: 2-s2.0-85046744871 05/12/2018
Correction to: Use of Genetic Testing for Primary Immunodeficiency Patients.

(Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Itan Y, Kobrynski L, Paris K, Torgerson TR, Verbsky JW, Wasserman RL, Hsieh EWY, Bleesing JJ, Chou JS, Lawrence MG, Marsh RA, Rosenzweig SD, Orange JS, Abraham RS.) J Clin Immunol. 2018 May;38(4):540-541 PMID: 29781065 SCOPUS ID: 2-s2.0-85047109391 05/22/2018
Use of Genetic Testing for Primary Immunodeficiency Patients.

(Heimall JR, Hagin D, Hajjar J, Henrickson SE, Hernandez-Trujillo HS, Tan Y, Kobrynski L, Paris K, Torgerson TR, Verbsky JW, Wasserman RL, Hsieh EWY, Blessing JJ, Chou JS, Lawrence MG, Marsh RA, Rosenzweig SD, Orange JS, Abraham RS.) J Clin Immunol. 2018 04;38(3):320-329 PMID: 29675737 SCOPUS ID: 2-s2.0-85045759261 04/21/2018

James Verbsky, MD, PhD